Digest

This podcast covers the diagnosis and treatment of heart failure with reduced ejection fraction (HFrEF), focusing on guideline-directed medical therapy (GDMT). Drs. Francootto and Williams review the importance of identifying the underlying cause of HFrEF, highlighting the role of diagnostic tools like BNP testing while acknowledging its limitations. The four pillars of GDMT—ARNI/ACE inhibitors, beta-blockers, mineralocorticoid antagonists, and SGLT2 inhibitors—are detailed, emphasizing the STRONG-HF trial's support for rapid initiation and titration. Practical application, including medication sequencing and monitoring patient response, is discussed, along with cost considerations and strategies for addressing incomplete GDMT through chart review. The importance of avoiding premature GDMT discontinuation, even with improved ejection fraction, is stressed. Less common medications like hydralazine/isosorbide dinitrate and ivabradine are mentioned, along with device therapy. The podcast concludes with listener questions addressing ED follow-up for heart failure patients and managing UTIs and fungal infections associated with SGLT2 inhibitors. The role of sodium restriction in diet is also discussed, emphasizing an individualized approach.

Outlines

00:01:41

Diagnosing and Treating HFrEF: A Comprehensive Guide

This episode introduces heart failure with reduced ejection fraction (HFrEF), its diagnosis (including the use and limitations of BNP testing), and the crucial role of guideline-directed medical therapy (GDMT). The four pillars of GDMT are explained, along with practical considerations for implementation, cost-effectiveness, and addressing incomplete therapy.

00:07:09

Optimizing GDMT and Addressing Challenges

This section focuses on the practical aspects of initiating and maintaining GDMT, including medication sequencing, monitoring patient response, and addressing financial barriers to access. It also covers strategies for avoiding premature discontinuation and managing side effects associated with SGLT2 inhibitors.

00:14:11

Advanced Therapies and Listener Questions

This segment discusses less common medications and treatments for HFrEF, such as hydralazine/isosorbide dinitrate and ivabradine, as well as device therapy. It concludes by answering listener questions regarding ED follow-up and managing infections related to SGLT2 inhibitor use.

Keywords

Q&A

• What are the four pillars of GDMT for HFrEF?

  ARNI/ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Rapid initiation and titration are crucial.

• Should GDMT be stopped if a patient improves?

  No, premature discontinuation leads to worse outcomes; maintaining GDMT is crucial for long-term success.

• How should clinicians manage UTIs or fungal infections in patients on SGLT2 inhibitors?

  Counsel patients proactively about the risk and emphasize hygiene. Treatment shouldn't necessitate discontinuation unless severe.

• What is the role of sodium restriction in managing HFrEF?

  Individualized approach; strict restriction may not significantly alter prognosis for all patients. Focus on a healthy overall diet.

• How should primary care physicians handle follow-up care for patients discharged from the ED after a heart failure exacerbation?

  Utilize institutional processes, perform chart reviews, and build relationships with ED colleagues for timely follow-up.

Show Notes